Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Seeking "Novel" Partnerships For Oncology Pipeline

This article was originally published in The Pink Sheet Daily

Executive Summary

The company has 13 drugs in development for oncology indications, "far more" than it can afford to develop on its own. Wyeth is not interested in out-licensing or divesting the candidates but instead will pursue a "novel" development partnership.

You may also be interested in...



Wyeth Aims For Two NME Launches A Year Under Retooled R&D Program

Changes to the R&D process include refocusing efforts on discovery of new molecular entities, with a reduced emphasis on line extensions. Only 23% of Wyeth’s portfolio is made up of line extensions versus 45% in 2001. Wyeth is also beginning to link scientist compensation to R&D goals.

Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says

The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.

CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says

Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel